-
Dongyangguang Pharmaceutical, Qilu...59 new drugs were approved for clinical trials, Hengrui’s 11th
Time of Update: 2021-09-13
3 billion imported blockbuster new drugs are reported for production; Two Class 1 new drugs of Zhengda Tianqing and Cinda were approved for clinical use; New anti-AD drug, the first domestic Tau antibody to apply for clinical application; Kelun, Hausen, CSPC.
-
New Drugs | Inventory of domestic production status of original research new drugs in the first
Time of Update: 2021-04-19
In China, the drug's marketing application was accepted by CDE in February 2021, and was subsequently included in the priority review for the indication β-thalassemia.
In China, the drug's marketing application was accepted by CDE and was subsequently included in priority review.
-
[drug gajun] among the approved new drugs in 2017, these 12 drugs have unlimited potential. CDE
Time of Update: 2018-03-26
In 2017, 12 new drugs were approved by FDA with unlimited potential In 2017, 47 new drugs were approved by FDA Recently, clarivate analytics, an American company, analyzed and predicted them It is est
-
Great news! Heavyweight new drugs are on the market, domestic anti-cancer new drugs enter FDA, drug
Time of Update: 2018-02-22
Good news: the US FDA approved the listing of Gilead new drug On February 8, Gilead Sciences announced that the US FDA approved the listing of its new drug biktarvy as a single tablet therapy once a d
-
Hausen won 13 first imitations, 6 new drugs, and 29 new drugs of class 1 menacing
Time of Update: 2023-01-05
Recently, Haosen Pharmaceutical's product line has made new progress: the introduction of heavy dual antibodies has been lavishly introduced, and the first clinical application of Class 1 new drug HS
-
In September, China, the United States and Europe approved the listing of new drugs 6 global new drugs were approved for marketing
Time of Update: 2022-11-04
Deucravacitinib (trade name: Sotyktu) is the world's first and currently the only approved oral selective tyrosine kinase 2 (TYK2) allosteric inhibitor developed by Bristol-Myers Squibb for the treatment of adult patients with moderate to severe plaque psoriasis.
-
The first GKA new drug disrupts the 30 billion diabetes market! Hengrui, Cinda, Haisco... NDA, star new drug inventory under research!
Time of Update: 2022-10-20
Dapagliflozin tablets sitagliptin phosphate tablets liraglutide injection insulin aspart 30 injection insulin glargine injection Diabetes medication (chemical/biological) in 2021 Top 10 varieties in hospital sales Data source: Yaorong Cloud National Hospital Sales Database 02 New drugs to be launched in 2022 are remarkable Compared with Hengrui's Henggliflozin, Microchip's siglita, Tanabe Mitsubishi Pharmaceutical's ticogliptin and other new drugs have been approved in China in 2021, there are fewer new drugs approved this year, but they are all remarkable and very eye-catching.
-
22 ophthalmology category 1 new drugs are coming to Hengrui, 3 new drugs are expected to be launched
Time of Update: 2022-05-01
Among the new ophthalmic drugs currently under development by the company, KH906 eye drops, a class 1 new drug, has entered Phase I clinical trials for the treatment of corneal neovascularization; KH737 eye drops, which have been approved for clinical use, are used to delay the progression of myopia in children .
-
Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return”?
Time of Update: 2022-01-12
Can Hengrui break through the “nine deaths and a lifetime” of new drug research and development?Wanchun Pharmaceutical’s core product Punablin was rejected from listing in the United States, plummeting 60%, and its market value fell to less than US$200 million .
-
Progress in new drugs Deqi Pharma's first new drug was approved for listing in China!
Time of Update: 2022-01-01
S. Food and Drug Administration (FDA) approved selinexor (XPOVIO®) combined with low-dose dexamethasone for the treatment of patients with refractory relapsed multiple myeloma (rrMM) .
In addition, Karyopharm announced that the ongoing phase 3 SIENDO trial of selinexor (XPOVIO®) for the treatment of endometrial cancer patients has completed the planned interim invalidity analysis.
-
Domestic Class 1 new drugs broke out! Cinda, Hausen... the sales of 12 innovative drugs soared, and the 21st Class 1 new drug was born this year
Time of Update: 2021-11-04
Since 2021, the number of Class 1 new drugs approved for marketing for the first time in China has reached 21, focusing on the fields of anti-tumor and anti-infection, and 9 new drugs are expected to participate in a new round of medical insurance negotiations .
-
Domestic Class 1 new drugs broke out! Sales of 12 innovative drugs soared, the 21st category 1 new drug was born this year
Time of Update: 2021-11-04
Since 2021, the number of Class 1 new drugs approved for marketing for the first time in China has reached 21, focusing on the fields of anti-tumor and anti-infection, and 9 new drugs are expected to participate in a new round of medical insurance negotiations .
-
Chia Tai Tianqing, Hausen, Hengrui...78 new drugs were approved for clinical use, Qilu biologics broke out, and influenza 1 new drugs struck
Time of Update: 2021-09-19
10) Approved domestic/imported new drug listing application Disulumab is a "first-in-class" anti-RANKL monoclonal antibody developed by Amgen, with global sales of approximately US$5 billion in 2020 .
-
incredible! Class 1 new drugs sold 10 billion, innovative drug companies "strike" the 100 billion
Time of Update: 2021-08-28
Sales of terminal protein kinase inhibitors in public medical institutions in China (unit: ten thousand yuan) Source: Mi Nei. com, China's public medical institutions terminal competition pattern With the increasing popularity of tinib drugs, Betta Pharmaceuticals has faced many challenges during the ten years when icotinib was launched on the market, including medical insurance negotiations, a 76.
-
27 new drugs were approved for clinical use, and “first-in-class” new drugs are still mainly introduced
Time of Update: 2021-08-09
Approved this time in China is a randomized, double-blind, controlled, adaptive phase 3 clinical study, which aims to evaluate the effectiveness and safety of 3D229 combined with paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer.
